KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) EBITDA: 2010-2025

Historic EBITDA for Pacira BioSciences (PCRX) over the last 16 years, with Sep 2025 value amounting to $6.4 million.

  • Pacira BioSciences' EBITDA rose 104.56% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.6 million, marking a year-over-year increase of 164.02%. This contributed to the annual value of -$73.4 million for FY2024, which is 183.69% down from last year.
  • Per Pacira BioSciences' latest filing, its EBITDA stood at $6.4 million for Q3 2025, which was down 25.14% from $8.5 million recorded in Q2 2025.
  • Over the past 5 years, Pacira BioSciences' EBITDA peaked at $39.9 million during Q2 2023, and registered a low of -$139.5 million during Q3 2024.
  • For the 3-year period, Pacira BioSciences' EBITDA averaged around $2.8 million, with its median value being $13.2 million (2024).
  • In the last 5 years, Pacira BioSciences' EBITDA soared by 587.52% in 2021 and then tumbled by 887.35% in 2024.
  • Quarterly analysis of 5 years shows Pacira BioSciences' EBITDA stood at $4.2 million in 2021, then plummeted by 334.93% to -$9.9 million in 2022, then soared by 435.27% to $33.2 million in 2023, then decreased by 25.52% to $24.7 million in 2024, then spiked by 104.56% to $6.4 million in 2025.
  • Its EBITDA stands at $6.4 million for Q3 2025, versus $8.5 million for Q2 2025 and $2.0 million for Q1 2025.